A multi-center randomized, placebo-controlled, double-blind, parallel group, phase IIb proof of concept study with 3 oral groups of AZD3480 during 12 weeks treatment of cognitive deficits in patients with schizophrenia

Trial Profile

A multi-center randomized, placebo-controlled, double-blind, parallel group, phase IIb proof of concept study with 3 oral groups of AZD3480 during 12 weeks treatment of cognitive deficits in patients with schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2012

At a glance

  • Drugs Ispronicline (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms HALO
  • Most Recent Events

    • 01 Jan 2012 Results published in the Schizophrenia Research.
    • 01 Jan 2012 Primary endpoint 'Assessment-scale-scores' has not been met.
    • 01 Jan 2012 Primary endpoint 'Cognitive-function-tests' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top